Live price temporarily unavailable.
Price history
Exelixis (EXEL) is a Health Care company in the Russell 1000. Latest news and coverage below.
Exelixis revenue & net income history (FY2016–FY2025)
RevenueNet income
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Jan 2020 | FY2020Jan 2021 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Jan 2025 | FY2025Jan 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $191.5M | $452.5M | $853.8M | $967.8M | $987.5M | $1.43B | $1.61B | $1.83B | $2.17B | $2.32B |
| Growth (year over year) | +415.0% | +136.3% | +88.7% | +13.3% | +2.0% | +45.3% | +12.3% | +13.6% | +18.5% | +7.0% |
| Gross profit | $184.9M | $437.4M | $827.5M | $934.7M | $951.3M | $1.38B | $1.55B | $1.76B | $2.09B | $2.24B |
| Gross margin | 96.6% | 96.7% | 96.9% | 96.6% | 96.3% | 96.3% | 96.4% | 96.0% | 96.5% | 96.4% |
| Operating income | −$28.1M | $165.9M | $438.9M | $369.5M | $110.1M | $286.7M | $201.5M | $170.9M | $604.6M | $872.2M |
| Operating margin | −14.7% | 36.7% | 51.4% | 38.2% | 11.1% | 20.0% | 12.5% | 9.3% | 27.9% | 37.6% |
| Net income | −$70.2M | $154.2M | $690.1M | $321.0M | $111.8M | $231.1M | $182.3M | $207.8M | $521.3M | $782.6M |
| Net margin | −36.7% | 34.1% | 80.8% | 33.2% | 11.3% | 16.1% | 11.3% | 11.4% | 24.0% | 33.7% |
| EPS (diluted) | −$0.28 | $0.49 | $2.21 | $1.02 | $0.35 | $0.72 | $0.56 | $0.65 | $1.76 | $2.78 |
| Balance sheet | ||||||||||
| Cash and equivalents | $151.7M | $183.2M | $314.8M | $266.5M | $319.2M | $647.2M | $501.2M | $263.0M | $217.4M | $482.5M |
| Total assets | $595.7M | $655.3M | $1.42B | $1.89B | $2.14B | $2.62B | $3.07B | $2.94B | $2.95B | $2.84B |
| Total liabilities | $506.4M | $370.3M | $134.8M | $199.7M | $258.2M | $405.6M | $583.1M | $678.4M | $703.5M | $683.1M |
| Long-term debt | $0 | $0 | — | — | — | — | — | — | — | — |
| Shareholders' equity | $89.3M | $285.0M | $1.29B | $1.69B | $1.88B | $2.21B | $2.49B | $2.26B | $2.24B | $2.16B |
| Cash flow | ||||||||||
| Operating cash flow | $210.4M | $165.6M | $415.7M | $527.0M | $209.0M | $400.8M | $362.6M | $333.3M | $700.0M | $884.3M |
| Capital expenditure | $1.70M | $21.1M | $33.3M | $12.8M | $30.3M | $54.2M | $27.7M | $40.5M | $28.4M | $8.43M |
| Free cash flow | $208.7M | $144.5M | $382.4M | $514.1M | $178.6M | $346.6M | $334.9M | $292.9M | $671.5M | $875.8M |
| Share buybacks | — | — | — | — | — | $0 | $0 | $550.4M | $652.0M | $947.5M |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24†Jan 2025 | Q1 FY25Apr 2025 | Q2 FY25Jul 2025 | Q3 FY25Oct 2025 | Q4 FY25†Jan 2026 | Q1 FY26Apr 2026 | Q2 FY26Jul 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $539.5M | $566.8M | $555.4M | $568.3M | $597.8M | $598.7M | $610.8M | $628.7M |
| Growth (year over year) | +14.3% | +18.2% | +30.6% | −10.8% | +10.8% | +5.6% | +10.0% | +10.6% |
| Gross profit | $522.2M | $546.8M | $536.3M | $548.8M | $579.2M | $572.2M | $590.9M | $608.0M |
| Gross margin | 96.8% | 96.5% | 96.5% | 96.6% | 96.9% | 95.6% | 96.7% | 96.7% |
| Operating income | $136.1M | $163.2M | $186.9M | $213.6M | $236.5M | $235.2M | $251.3M | $248.4M |
| Operating margin | 25.2% | 28.8% | 33.6% | 37.6% | 39.6% | 39.3% | 41.1% | 39.5% |
| Net income | $118.0M | $139.9M | $159.6M | $184.8M | $193.6M | $244.5M | $210.5M | $212.1M |
| Net margin | 21.9% | 24.7% | 28.7% | 32.5% | 32.4% | 40.8% | 34.5% | 33.7% |
| EPS (diluted) | $0.40 | $0.47 | $0.55 | $0.65 | $0.69 | $0.89 | $0.79 | $0.82 |
| Balance sheet | ||||||||
| Cash and equivalents | $258.3M | $217.4M | $183.8M | $164.4M | $376.3M | $482.5M | $226.2M | $281.4M |
| Total assets | $2.96B | $2.95B | $2.84B | $2.68B | $2.82B | $2.84B | $2.59B | $2.49B |
| Total liabilities | $684.9M | $703.5M | $706.2M | $644.5M | $662.8M | $683.1M | $657.8M | $650.5M |
| Shareholders' equity | $2.28B | $2.24B | $2.13B | $2.03B | $2.16B | $2.16B | $1.94B | $1.84B |
| Cash flow | ||||||||
| Operating cash flow | $271.3M | $240.3M | $211.4M | $49.0M | $290.3M | $333.5M | $251.8M | $307.7M |
| Capital expenditure | $8.20M | $3.98M | $2.95M | $2.84M | $1.48M | $1.16M | $1.51M | $6.82M |
| Free cash flow | $263.1M | $236.3M | $208.5M | $46.2M | $288.8M | $332.4M | $250.3M | $300.9M |
| Share buybacks | $11.9M | $190.4M | $283.9M | $301.9M | $104.0M | $257.6M | $430.4M | $323.0M |
From Exelixis's 10-K and 10-Q filings with the SEC; its fiscal year ends in January. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Exelixis
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
- Headquarters
- Alameda, California From SEC filings, Oct 2026
Recent News
No recent news mentioning Exelixis in our feed yet.
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International